2025-10-30 - Analysis Report
Okay, let's break down the analysis of Johnson & Johnson (JNJ) based on the provided data.

**Report in English**

**1. Relative Performance:**

*   **Ticker:** JNJ (Johnson & Johnson)
*   **Description:** Johnson & Johnson is a global healthcare company that develops and manufactures pharmaceuticals, medical devices, and consumer health products.
*   **JNJ Cumulative Return:** 42.56%
*   **S&P 500 (VOO) Cumulative Return:** 104.04%
*   **Absolute Deviation:** -51.4%
*   **Deviation Range:** Max: 16.5%, Min: -65.5%
*   **Relative Deviation:** 17.2% (Indicates JNJ's performance is near the lower end of its historical deviation range compared to the S&P 500).

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD     | Alpha  | Beta   | Cap(B) |
|------------|---------|---------|--------|--------|--------|
| 2015-2017  | 26.0%   | 66.8%   | -2.0%  | -0.1   | 336.7  |
| 2016-2018  | 14.0%   | 10.7%   | -1.0%  | 0.1    | 310.9  |
| 2017-2019  | 20.0%   | 71.5%   | -2.0%  | 0.4    | 351.5  |
| 2018-2020  | 19.0%   | 79.2%   | -4.0%  | 0.4    | 379.2  |
| 2019-2021  | 33.0%   | 79.2%   | -14.0% | 0.5    | 412.2  |
| 2020-2022  | 8.0%    | 79.6%   | 9.0%   | 0.4    | 425.6  |
| 2021-2023  | -19.0%  | 79.6%   | -20.0% | 0.3    | 377.7  |
| 2022-2024  | -32.0%  | 79.6%   | -53.0% | 0.3    | 348.5  |
| 2023-2025  | 14.0%   | 79.6%   | -55.0% | 0.1    | 446.1  |

**Analysis:**

*   **Underperformance:** JNJ has significantly underperformed the S&P 500 based on cumulative returns. The relative deviation of 17.2% further emphasizes this point.
*   **Alpha and Beta Trends:** The negative alpha values in most periods suggest that JNJ has consistently underperformed its expected return based on its beta.  The beta values are relatively low, indicating lower volatility compared to the overall market. High Maximum Drawdown (MDD) indicate high risk.

**2. Recent Price Action:**

*   **Current Price:** 185.13
*   **Last Market Close:** Price: 185.15, Previous Close: 186.93, Change: -0.95
*   **5-day Moving Average:** 190.248
*   **20-day Moving Average:** 190.1773
*   **60-day Moving Average:** 181.1892

**Analysis:**

*   **Price Decline:** The recent price of 185.13 and change of -0.95 suggests a slight recent dip.
*   **Moving Averages:** The price is below both the 5-day and 20-day moving averages, indicating potential short-term downward momentum. However, it's above the 60-day moving average, suggesting a longer-term uptrend.

**3. Risk Indicators and Expected Return:**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 34.64 (Approaching oversold territory)
*   **PPO:** -0.52 (Below zero, suggesting a downtrend)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (5 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Delta_Previous_Relative_Divergence:** -2.3 (Short-term decline)
*   **Expected Return:** -102.1% (Significantly negative, indicating potential long-term underperformance compared to the S&P 500)
*   **Recent Price Change:** The Last-market data indicates a recent downward fluctuation (price decrease).

**Analysis:**

*   **High MRI, Low RSI:** MRI suggests to buy, but RSI is approaching oversold territory.
*   **Divergence:** The negative divergence indicates further price weakness in the short term.
*   **Concerning Expected Return:** The very negative expected return is a major red flag.

**4. Recent News & Significant Events:**

*   **Positive:** Johnson & Johnson is conducting studies on its drug Imaavy.
*   **Negative:** Downgrade from Freedom Capital. Jury award against JNJ in a talc mesothelioma case. Texas lawsuit regarding Tylenol and a link to autism.

**Analysis:**

*   **Mixed Sentiment:** The news is a mix of positive developments (drug studies) and negative events (lawsuits, downgrade). The lawsuits are a significant concern.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (Mean = 2.17)
*   **Target Price:** Average: 199.56, High: 225.00, Low: 155.00
*   **Recent Rating Changes:** No recent changes indicated.

**Analysis:**

*   **Analyst Optimism:** Despite the underperformance, analysts generally have a positive outlook on the stock. The average target price suggests potential upside.

**5. Recent Earnings Analysis:**

| 날짜         | EPS   | 매출        |
|--------------|-------|-------------|
| 2025-10-22   | 2.14  | 23.99 B$    |
| 2025-07-24   | 2.3   | 23.74 B$    |
| 2025-04-23   | 4.57  | 21.89 B$    |
| 2024-10-23   | 1.12  | 22.47 B$    |
| 2025-10-22   | 1.12  | 22.47 B$    |

**Analysis:**

*   **Mixed EPS:** EPS has been volatile, with a significant jump in 2025-04-23.
*   **Stable Revenue:** Revenue has been relatively stable over the past few quarters.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-06-30   | $23.74B    | 67.87%       |
| 2025-03-31   | $21.89B    | 66.40%       |
| 2024-12-31   | $22.52B    | 68.35%       |
| 2024-09-30   | $22.47B    | 69.01%       |
| 2024-06-30   | $22.45B    | 69.40%       |

**Capital and Profitability:**

| Quarter      | Equity     | ROE    |
|--------------|------------|--------|
| 2025-06-30   | $78.47B    | 7.06%  |
| 2025-03-31   | $78.11B    | 14.08% |
| 2024-12-31   | $71.49B    | 4.80%  |
| 2024-09-30   | $70.16B    | 3.84%  |
| 2024-06-30   | $71.54B    | 6.55%  |

**Analysis:**

*   **High Profit Margins:** JNJ maintains very high profit margins, indicating strong pricing power.
*   **Fluctuating ROE:** ROE has been volatile, suggesting variability in how efficiently the company is using equity to generate profits.

**7. Overall Analysis:**

*   **Underperformance:** JNJ has significantly underperformed the S&P 500.
*   **Mixed Signals:**  Technical indicators present a mixed picture (RSI nearing oversold, PPO negative).
*   **Analyst Optimism vs. Expected Return:** Analysts are generally positive, but the significantly negative expected return is concerning.
*   **Legal Risks:** The ongoing lawsuits represent a significant risk factor.
*   **Financial Strength:** JNJ has strong financials (high profit margins, stable revenue).

**Conclusion:**

Based on the provided data, JNJ presents a mixed investment case. While the company exhibits financial strength and analysts have a positive outlook, the underperformance relative to the S&P 500, negative expected return, and ongoing legal challenges are significant concerns. Further research is warranted before making an investment decision. The recent price decline and mixed technical signals suggest caution in the short term.
